Clinical Trial Update: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a triplet of amivantamab, lazertinib, and bevacizumab for EGFR-mutant advanced non-small cell lung cancer after progression on a third-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• Bevacizumab (bevacizumab)
• Lazertinib (lazertinib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING